Abstract Number: 169 • 2014 ACR/ARHP Annual Meeting
Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Background/Purpose: Diabetes is a well-recognized risk factor for heart disease, increasing the risk of heart disease by 2-3 fold in many studies. Recent ACC/AHA lipid…Abstract Number: 168 • 2014 ACR/ARHP Annual Meeting
Positive Association Between Tomato Consumption and Serum Urate: Investigating an Anecdotal Trigger of Gout Flares
Background/Purpose: Gout is characterised by intermittent flares of inflammation in response to monosodium urate crystals in the joints. Gout flares can be triggered by dietary…Abstract Number: 167 • 2014 ACR/ARHP Annual Meeting
Target Serum Urate: Do Patients Know Their Goal?
Background/Purpose: Treat-to-target approaches are used to achieve therapeutic goals in conditions such as diabetes and rheumatoid arthritis. This strategy has also been widely endorsed in…Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting
Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment
Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…Abstract Number: 165 • 2014 ACR/ARHP Annual Meeting
Prevalence of Gout in the Adult Population of France in 2013
Background/Purpose The prevalence of gout has been studied in several Western countries by various methods to approach gout diagnosis, and has been estimated to vary…Abstract Number: 164 • 2014 ACR/ARHP Annual Meeting
Gouty Patients with History of Adverse Reaction to Allopurinol Are Not at Higher Risk of Reaction to Febuxostat
Background/Purpose Allopurinol is the standard drug for urate-lowering management of gout. Allopurinol is safe in most patients. The most frequent side effects are minor cutaneous…Abstract Number: 163 • 2014 ACR/ARHP Annual Meeting
Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat
Background/Purpose: Allopurinol can lead to skin toxicity. Minor skin reactions are reported in 2-4% of patients and life threatening severe cutaneous reactions (SCARs) in 0.1-0.4%.…Abstract Number: 162 • 2014 ACR/ARHP Annual Meeting
Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises
Background/Purpose There are currently no agreed remission criteria for gout. The aim of this study was to establish consensus for elements of potential remission criteria…Abstract Number: 161 • 2014 ACR/ARHP Annual Meeting
Ultrasonographic Measurement of Renal and Carotid Artery Resistive Indices and Diastolic Function of the Heart in Gout Patients
Background/Purpose Our aim was to assess the impact of gout on kidneys, diastolic function of the heart and carotid arteries. We examined ultrasonographic parameters that…Abstract Number: 160 • 2014 ACR/ARHP Annual Meeting
All Men with Gout Should be Screened for Erectile Dysfunction
Background/Purpose Erectile dysfunction (ED) is common in the general population. The likelihood of ED increases progressively with age; however, it is not an inevitable consequence…Abstract Number: 159 • 2014 ACR/ARHP Annual Meeting
Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-Steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up
Background/Purpose Frequently flaring acute gouty arthritis (GA) patients (pts), in whom NSAIDs and/or colchicine are contraindicated, not tolerated or ineffective, need effective alternative treatments.1 Canakinumab…Abstract Number: 157 • 2014 ACR/ARHP Annual Meeting
Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis
Background/Purpose The gold standard for the diagnosis of acute MSU induced arthritis is crystal identification by microscopy after joint aspiration. Alternative diagnostic tools that have…Abstract Number: 176 • 2014 ACR/ARHP Annual Meeting
Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both
Background/Purpose: Gout is associated with increased CV risk, both dependent on, and independent of traditional CV risk factors. Recent studies suggest that OA, traditionally considered non-inflammatory,…Abstract Number: 174 • 2014 ACR/ARHP Annual Meeting
Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study
Background/Purpose: Gouty arthritis (GA) patients who experience frequent flares and have comorbidities have limited treatment options. Canakinumab (CAN), a selective, human, anti-interleukin1β monoclonal antibody, has…Abstract Number: 173 • 2014 ACR/ARHP Annual Meeting
Self-Management Education for Patients with Gout: A Review of Existing Resources
Background/Purpose Inadequate patient self-management education resources may contribute to poor management and outcomes for gout. Patient education resources need to be easy to read and…